Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.

BMC Cancer · 2012 · PMC3488582 · PMID 23013471

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Our data neither supports nor contradicts the hypothesis that tipifarnib is acting in part as a Pgp inhibitor: in CD34 + CD38 - cells median cell kill in the 9 Pgp + samples increased from 15% with tipifarnib and 5% with GO to 52% with the combination, but an increase was only recorded in 6/9 samples and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.